Barnes & Noble Education Stock (NYSE: BNED)

Barnes & Noble Education (NYSE:BNED) Stock

Barnes & Noble Education

Barnes & Noble Education Inc is an operator of bookstores in college and university campuses across the United States. The company is also engaged in providing digital education services. It operates in three reportable segments that include Retail offers existing and prospective clients the flexibility of physical, virtual, or custom store solutions, and wholesale is comprised of the wholesale and virtual retail fulfillment, and support operations of the MBS subsidiary, also Corporate Services represent unallocated shared-service costs which include corporate level expenses and other governance functions, including executive functions, such as accounting, legal, treasury, information technology, and human resources. It earns majority of the revenue from Retail segment.

Baird analyst Michael Halloran maintains Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) with a Outperform and raises the price target from $107 to $121.

News

Price Target

Analyst Ratings

Baird Maintains Outperform on Pentair, Raises Price Target to $121

Barclays analyst David Anderson maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Equal-Weight and lowers the price target from $26 to $22.

Barclays Maintains Equal-Weight on Halliburton, Lowers Price Target to $22

Barclays analyst Julian Mitchell maintains GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) with a Overweight and raises the price target from $230 to $295.

Barclays Maintains Overweight on GE Aerospace, Raises Price Target to $295

Baird analyst Peter Arment maintains Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) with a Neutral and raises the price target from $547 to $565.

Baird Maintains Neutral on Northrop Grumman, Raises Price Target to $565

Guggenheim analyst Jason Cassorla maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $180 to $188.

Guggenheim Maintains Buy on Tenet Healthcare, Raises Price Target to $188

Baird analyst Ben Kallo maintains MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) with a Outperform and raises the price target from $52 to $69.

Baird Maintains Outperform on MP Materials, Raises Price Target to $69

During Conf Call, Hasbro CFO Says Expects $60M In Expenses In Its 2025 P&L Due To Tariffs

Guggenheim analyst Yatin Suneja maintains Abivax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) with a Buy and raises the price target from $50 to $101.

ABVX

Guggenheim Maintains Buy on Abivax, Raises Price Target to $101

Barclays analyst Manav Patnaik maintains Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Equal-Weight and lowers the price target from $260 to $240.

Barclays Maintains Equal-Weight on Equifax, Lowers Price Target to $240

Baird analyst Peter Arment maintains Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) with a Outperform and lowers the price target from $540 to $500.

Baird Maintains Outperform on Lockheed Martin, Lowers Price Target to $500

DuringConf Call, At&T Says Expects Q3 Capital Investment Between $5B-$5.5B

Barclays analyst Betty Jiang maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight and raises the price target from $65 to $68.

Barclays Maintains Overweight on EQT, Raises Price Target to $68

Baird analyst Ghansham Panjabi maintains Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) with a Neutral and raises the price target from $105 to $110.

Baird Maintains Neutral on Crown Holdings, Raises Price Target to $110

Baird analyst Robert Mason maintains Badger Meter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) with a Neutral and raises the price target from $216 to $219.

Baird Maintains Neutral on Badger Meter, Raises Price Target to $219

Barclays analyst Brendan Lynch maintains Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) with a Overweight and raises the price target from $113 to $117.

Barclays Maintains Overweight on Crown Castle, Raises Price Target to $117

NNVC

NanoViricides Intends To File For Orphan Drug Status For Several Indications Of NV-387, Including MPox, Smallpox, And Measles

Baird analyst Eric Coldwell maintains Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) with a Neutral and raises the price target from $313 to $490.

MEDP

Baird Maintains Neutral on Medpace Hldgs, Raises Price Target to $490

WIIM

DTIL

DTIL stock has given up its prior gain. Precision BioSciences shares were trading higher after the company was granted FDA orphan drug designation for PBGENE-DMD in Duchenne muscular dystrophy.

<a href="https://www.jnj.com/media-center/press-releases/european-commission-approves-imbruvica-ibrutinib-as-the-first-targeted-therapy-for-patients-with-previously-untreated-mantle-cell-lymphoma-who-would-be-eligible-for-autologous-stem-cell-transplant" title="https://www.jnj.com/media-center/press-releases/european-commission-approves-imbruvica-ibrutinib-as-the-first-targeted-therapy-for-patients-with-previously-untreated-mantle-cell-lymphoma-who-would-be-eligible-for-autologous-stem-cell-transplant">https://www.jnj.com/media-center/press-releases/european-commission-approves-imbruvica-ibrutinib-as-the-first-targeted-therapy-for-patients-with-previously-untreated-mantle-cell-lymphoma-who-would-be-eligible-for-autologous-stem-cell-transplant</a>

Biotech

Government

Regulations

General

'European Commission Approves IMBRUVICA (ibrutinib) As The First Targeted Therapy For Patients With Previously Untreated Mantle Cell Lymphoma Who Would Be Eligible For Autologous Stem Cell Transplant' - Johnson & Johnson

NanoViricides, Inc., a publicly traded company (NYSE Amer.:<a href="https://pr.report/ckhj">NNVC</a> ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains that the strong effectiveness of its broad-spectrum antiviral drug against all viruses that the drug NV-387 was tested against to date will drive significant valuation for its portfolio. The Company further elucidates that the MPox, Smallpox, and Measles indications of NV-387 are expected to enable rapid regulatory development towards approval and realization of early revenues from multiple pathways.
As additional indications of NV-387 have been validated in animal studies, approvals against the multiple indications of NV-387 are expected to drive increase in overall market share that the Company can achieve once the drug is approved. The costs leading up to Phase II clinical trial would be substantially common across all indications of this same drug, improving return on investment significantly.
Additionally, NV-387 should become the drug of choice to develop and stockpile for strategic pandemic preparedness and response because of its activity against most of the viruses of concern at present: Influenza, Coronaviruses, Orthopoxviruses (Smallpox and Mpox), and Measles. The Company believes that NV-387 is likely to be effective against Ebola/Marburg viruses, Hendra/Nipah viruses, and other lethal viruses as well, based on known binding of these viruses to HSPG. In addition to the USA, UK, Europe and India have established agencies to enable pandemic preparedness and response.
Approval of NV-387 against any of the currently established indications would drive its value as a strategic tool for pandemic preparedness against a multiplicity of potential threats. Pandemic preparedness is already a multi-billlion dollar market globally, and growing, as additional countries and regions seek to fortify their public health defenses against unknown viral threats. (see further below).
To this end, the Company is moving forward to open a Phase II clinical trial to evaluate effectiveness of NV-387 to treat MPox virus infections. If the trial is successful, NV-387 will be the first ever drug to be approved for MPox [1] . There is no effective drug for MPox at present.
Such approval will also translate to NV-387 as a currently best available option for potential smallpox therapeutics as well, based on human infection data of the smallpoxvirus-related virus MPXV , rather than animal orthopoxvirus data that FDA has currently relied upon [1] .
Additionally, the Company intends to file for orphan drug status for several indications of NV-387, including MPox, Smallpox, and Measles. Each orphan drug indication in itself would result in several economic benefits, in addition to increased interactions with the FDA.
We believe some of the indications of NV-387 will be eligible for Fast-Track designation, as well as for awards of Priority Review Vouchers (PRV). A PRV is a tradable instrument that has been traded at about $150 million to $250 million dollars each because the buying pharma company can apply the PRV for any one drug to expedite its own drugs in development. Thus PRVs could enable an early revenue source for the Company if awarded.
The speed with which a first indication of NV-387 can be approved is estimated to be the fastest for Mpox, Smallpox, and Measles. This is because of the specific orphan drug characteristics of these diseases in the USA. This is why the Company has prioritized these indications.
The Company is continuing its work on planning of clinical trials for what are generally considered as commercially lucrative indications that include Influenza, RSV, other respiratory viruses, as well as coronaviruses.
Viruses crossing over newly into humans from other species do so only upon acquiring significant ability to bind to HSPG, the cell-side molecule that NV-387 mimics as a decoy for the viruses [2] . It is highly unlikely that bioterrorism agents would be created that can drastically infect humans and yet do not bind to HSPG.
To date, pandemic preparedness has been dominated by one-drug-one-bug philosophy. With hundreds of potential biothreats, such a strategy is too expensive and would not realize a highly effective protective shield against potential pandemics.
Besides, the medical countermeasures pursued to-date for pandemic preparedness are severely lacking in that every one of them would be readily defeated by the virus as it mutates or evolves in the field. This is one lesson that has become starkly clear after the COVID-19 pandemic.
NV-387 is expected to provide a low cost option for pandemic preparedness against a multiplicity of threats, and could become an effective first response drug for practically any viral pandemic. Over 90% of viruses that can cause disease in humans are known to bind to HSPG. Our development of NV-387 suggests that most of these viruses would be susceptible to NV-387. Moreover, escape from NV-387 is highly unlikely because even as viruses mutate or evolve, they continue to bind well to HSPG as long as they are pathogenic in humans.

NanoViricides Highlights Broad Antiviral Effectiveness Of NV-387; Expects Accelerated Development And Early Revenues From MPox, Smallpox, And Measles Indications

Press Releases

Immersion Corporation Reports Second Quarter 2024 Results

Earnings

Barnes & Noble Education Reports First Quarter Fiscal Year 2025 Financial Results

Barnes & Noble Education Reports Second Quarter Preliminary Fiscal Year 2025 Unaudited Financial Results

Barnes & Noble College Announces Strategic Partnership with Syracuse University

North Carolina A&T Returns to Barnes & Noble College to Manage its Campus Bookstore

Barnes & Noble Education Continues its Strong Expansion of First Day® Affordable Access Programs

Barnes & Noble Education Reports Second Quarter Fiscal Year 2025 Financial Results

Barnes & Noble Education Strengthens Leadership Team with the Appointment of Christopher Neumann as General Counsel & Corporate Secretary and Gary Luster as Chief Accounting Officer

Barnes & Noble Education Reports Third Quarter Fiscal Year 2025 Financial Results

Barnes & Noble Education Announces Surge in New Campus Store Partnerships

BNED

IMMR

Academy Sports and Outdoors, Inc. - Common Stock

Academy Sports

BARK

Build-A-Bear Workshop

Bath & Body Works

Barnes & Noble Education, Inc Common Stock

Chewy

Dick's Sporting Goods

Envela

National Vision Holdings, Inc. - Common Stock

National Vision Holdings

Five Below

1-800-FLOWERS.COM, Inc. - Class A Common Stock

1-800-Flowers.com

Grove Collaborative Holdings, Inc. Class A Common Stock

Grove Collaborative Hldgs

MarineMax

Leslies

PetMed Express

Pitanium Limited - Class A Ordinary Shares

Pitanium

Sally Beauty Holdings, Inc. (Name to be changed from Sally Holdings, Inc.) Common Stock

Comments

Barnes & Noble Education

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL